News Hub | News Direct

All Industries


Article thumbnail News Release

Elutia's CanGarooRM: Pioneering Drug-Eluting Biologic for Secure Medical Implants

Elutia Inc.

Elutia CEO Randy Mills joined Steve Darling from Proactive to discuss the company's groundbreaking product, CanGarooRM, a drug-eluting biologic designed to safeguard implanted medical devices such as pacemakers. Founded by Mills and Kevin Rakin, both esteemed veterans in the biotech industry, Elutia aims to revolutionize healthcare by combining regenerative medicine with localized drug delivery. Mills shed light on CanGarooRM's unique formulation, which includes antibiotics to prevent infections and device migration, ultimately enhancing patient safety. With the FDA accepting their filing in December, Elutia is optimistic about receiving favorable results in the second quarter of this year. If approved, CanGarooRM has the potential to capture a significant share of the market, estimated to exceed $500 million. Mills further elaborated that Elutia has completed product development and is poised to commence commercial production by the late second quarter. A soft launch is planned for the third quarter, followed by full-scale deployment by the fourth quarter of this year. This strategic timeline positions Elutia for substantial growth pending regulatory approval, with CanGarooRM poised to address critical needs in the healthcare industry and improve patient outcomes. In summary, the interview underscored Elutia's promising trajectory and the transformative potential of CanGarooRM in enhancing medical device safety. With a strong foundation in regenerative medicine and localized drug delivery, Elutia is poised to make a significant impact in healthcare innovation, driving positive change and improving patient care globally. Contact Details Proactive North America Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

February 20, 2024 10:37 AM Eastern Standard Time

Video
Article thumbnail News Release

Hive Digital sees 146% increase in Gross Operating Margins as company releases Q3 earnings report

HIVE Digital Technologies

Hive Digital Technologies CEO Aydin Kilic joined Steve Darling from Proactive to announce the company's earnings report for the third quarter. Kilic revealed that the company achieved remarkable revenue of $30.1 million during this quarter, primarily attributed to mining 830 Bitcoin. Notably, the Gross Operating Margin stood at an impressive 38%, translating to $11.3 million in income from digital currency mining operations. Kilic highlighted that these figures represent a significant 146% increase in Gross Operating Margin compared to the previous quarter. He attributed the stronger Bitcoin mining economics to the rally in Bitcoin prices, potentially fuelled by the news surrounding Bitcoin ETFs in the United States and the subsequent SEC approval on January 10, 2024. In addition to revenue from Bitcoin mining, the company realized $0.9 million in revenue during the quarter from its GPU-powered High Performance Computing business unit. This segment leverages the company's GPUs for various AI computations, including inference and fine-tuning of large language models. Overall, these impressive financial results underscore Hive Digital Technologies' strong performance in the cryptocurrency mining sector and its strategic diversification into other high-growth areas such as AI computation. Contact Details Proactive North America Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

February 20, 2024 10:32 AM Eastern Standard Time

Video
Article thumbnail News Release

Simply Solventless Concentrates announces new VP as company plans 2024 products launch

Simply Solventless Concentrates

Simply Solventless Concentrates CEO Jeff Swainson joins Steve Darling from Proactive to share exciting updates regarding the company's upcoming activities. Simply Solventless Concentrates anticipates a busy month ahead, with approximately $1.25 million in purchase orders lined up from Alberta and Ontario. Additionally, the company is set to launch six third-party branded products in Alberta and one in Ontario, further expanding its market presence. Swainson underscored the importance of strategic leadership in supporting the company's growth trajectory. To this end, Simply Solventless Concentrates announced the appointment of Jeff Lawrence to the position of Vice President, Marketing & Sales. Lawrence brings over 30 years of experience in industrial and consumer packaged goods, including five years in the cannabis industry. With a proven track record of driving sales growth and propelling startups through strategic development, team building, and effective leadership, Lawrence is poised to make a significant impact on the company's sales and marketing initiatives. Swainson highlighted Lawrence's previous role as National Director of Sales at Dycar Pharmaceuticals, where he played a key role in overseeing the launch of four brands and scaling store listings from 70 to over 2,200 across five provinces. Lawrence's extensive experience and leadership acumen make him a valuable addition to the Simply Solventless Concentrates team, positioning the company for continued success and expansion in the competitive cannabis market. With a robust pipeline of purchase orders and new product launches on the horizon, Simply Solventless Concentrates is primed for growth under Lawrence's leadership. Stay tuned for further updates as the company continues to execute its strategic initiatives and capitalize on emerging opportunities in the cannabis industry. Contact Details Proactive North America Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

February 20, 2024 10:29 AM Eastern Standard Time

Video
Article thumbnail News Release

CervoMed appoints drug development veteran Dr. Joshua Boger as Chairman of the Board

CervoMed

CervoMed Inc CEO John Alam joined Steve Darling from Proactive to announce a significant addition to the company's leadership team. CervoMed has appointed Joshua Boger to its Board of Directors as Chair, leveraging his wealth of experience in drug development and biopharmaceutical leadership to drive the company's strategic initiatives forward. Dr. Boger is a seasoned industry veteran with over 40 years of experience, renowned for his innovative approach to science and proven track record as a business executive. Currently serving as Executive Chairman of Alkeus Pharmaceuticals, Dr. Boger brings invaluable insights and expertise to CervoMed. Alam elaborated on the significance of Dr. Boger's appointment and the pivotal phase the company is entering, with topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod in dementia with Lewy bodies (DLB) expected in the second half of 2024. Neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha, holds immense promise in addressing synaptic dysfunction, particularly in the basal forebrain cholinergic system, which is most impacted in DLB. Drawing from preclinical studies and clinical trials involving over 300 participants, Alam highlighted neflamapimod's favorable safety profile and its significant impact on dementia severity as demonstrated in the AscenD-LB Phase 2a clinical study. These promising results underscore the potential of neflamapimod to address the unmet medical needs in DLB and pave the way for transformative treatment options. The appointment of Dr. Boger and the advancements in CervoMed's clinical trials signify a significant milestone in the company's mission to develop innovative therapies for neurodegenerative diseases. With a visionary leadership team and a promising pipeline of treatments, CervoMed is poised to make a meaningful impact on the lives of patients and caregivers affected by DLB and related conditions. Stay tuned for further updates as CervoMed continues its journey towards advancing neurological healthcare. Contact Details Proactive North America Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

February 20, 2024 10:22 AM Eastern Standard Time

Video
Article thumbnail News Release

Madison Metals announces high-grade discover at Anomaly 5 at Khan Project

Madison Metals Inc

Madison Metals CEO Duane Parnham joined Steve Darling from Proactive to unveil a significant milestone in the company's exploration efforts. Madison Metals has made a remarkable discovery of high-grade uranium mineralization at Anomaly 5, located within the Company’s Khan Project in Namibia. The findings, highlighted by a surface sample boasting 8.47% U3O8, mark a substantial expansion of new uranium mineralization, effectively extending Madison’s footprint and project pipeline. During the interview, Parnham elaborated on Madison's exploration strategy, which commenced with the initial fieldwork to ground-truth airborne radiometric anomalies. This groundwork paved the way for follow-up exploration activities, which included the excavation of seven surface rock-saw trenches, leucogranite mapping, sampling, and handheld scintillometer and spectrometer readings at Anomaly 5. The initial batch of assay results from 10 samples returned promisingly high uranium grades, further bolstering the company's confidence in the potential of Anomaly 5. Parnham emphasized that Madison Metals plans to release additional assay results as they become available, providing stakeholders with further insights into the extent and significance of the discovered mineralization. The discovery of high-grade uranium mineralization at Anomaly 5 represents a pivotal moment for Madison Metals, reaffirming the company's commitment to unlocking the full potential of its projects in Namibia. With a strategic focus on exploration and a track record of delivering results, Madison Metals is well-positioned to capitalize on the growing demand for uranium and solidify its position as a key player in the global mining sector. Stay tuned for further updates as the company's exploration efforts continue to unfold. Contact Details Proactive North America Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

February 20, 2024 10:16 AM Eastern Standard Time

Video
Article thumbnail News Release

Cloud DX secures key partnership with Sanrai International for worldwide distribution

Cloud DX

Cloud DX CEO Robert Kaul joined Steve Darling from Proactive to announce a new Partnership Agreement with New York-based Sanrai International. Sanrai International, a leading medical device distribution company with a global presence, will now market and resell the Cloud DX Connected Health platform across more than 65 countries. Kaul highlighted the significance of this partnership, emphasizing Sanrai's extensive customer and sub-distributor network, which spans Latin America, Africa, the Middle East, Asia, and beyond. The focus of this collaboration will be on addressing chronic disease management and post-surgical recovery, leveraging Cloud DX's innovative Connected Health products and services. With the partnership in place, both Cloud DX and Sanrai aim to equalize access to innovative medical devices, particularly in the areas of chronic illness and post-surgical recovery. Kaul also mentioned that Cloud DX has already announced over $2.5 million CAD in new business in 2024, reflecting the company's continued growth and market expansion efforts. Contact Details Proactive North America Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

February 20, 2024 10:06 AM Eastern Standard Time

Video
Article thumbnail News Release

Bitcoin To Surge To $70k As Traders Look Forward To the 'Year of the Dragon', Sui and KangaMoon To Lead the Altcoin Rally

Kangamoon

East Asia is preparing to celebrate the start of the Year of the Dragon in the next few weeks. Crypto traders are excited, anticipating a major rally for Bitcoin as the year is considered one of the luckiest and most prosperous animals in the Chinese Zodiac. Ahead of the celebration, Markus Thielen has forecasted that Bitcoin could peak above $70k before the year ends. Meanwhile, two altcoins, Sui (SUI) and KangaMoon (KANG), are gearing up to lead the altcoin market rally in 2024. Markus Thielen Forecasts a Surge To $70,000 for Bitcoin (BTC) Markus Thielen, a famous crypto analyst at 10X Research, predicts that the Bitcoin (BTC) price will rise to $70,000 by the end of the year. This implies a 65% increase over the current $42,500 - $43,000 range, where the Bitcoin price has remained unchanged for more than a week. Thielen depends on his positive projections on strengthening macro conditions, the U.S. elections, monetary tailwinds, and growing demand for spot Bitcoin ETFs. His claims are bolstered by the increasing attitude in the cryptocurrency industry. On February 10, East Asia will begin the Year of the Wood Dragon. Crypto traders anticipate that the crypto market will suffer the same fate as one of the Chinese Zodiac's luckiest and most affluent animals. As the Bitcoin price increases, the altcoin market is expected to surge in 2024. Sui (SUI) TVL Sets New ATH, Price To Follow With the broader crypto market looking bullish, Sui (SUI) is one of the top altcoins that could take advantage. Over the past few months, the Sui network has grown at an incredible rate, with its total value locked (TVL) increasing by more than 1,000%. According to DeFiLlama data, Sui has a TVL of more than $515 million, making it the ninth-largest DeFi project. The growth of the Sui network can be linked to the rapid development of dApps with real-world use cases. With the network continuing to grow, experts expect the Sui coin to soar in 2024. Year-to-date (YTD), Sui has gained more than 100% to trade at the $1.5 range. However, as the network growth continues, a 30% surge to take SUI to a new ATH is expected, making it one of the top altcoins to buy. KangaMoon (KANG) To Dominate the 2024 Altcoin Market Rally In the upcoming altcoin market rally, KangaMoon (KANG) has been picked by experts as one of the top altcoins to watch. Built around an exciting new concept, the KANG token has been predicted to record a parabolic 100x price surge before the year ends. The DeFi project has attracted this kind of prediction because of its unique Social Finance (Social-Fi) network in the works. The platform also combines elements of play-to-earn, NFTs, and meme coins. This Social-Fi ecosystem aims to become the ultimate hub for meme coin enthusiasts. KangaMoon was designed to encourage interaction among meme coin enthusiasts and reward them for their participation. As the players participate in weekly, monthly, and quarterly challenges and special giveaways, they will earn KANG tokens and other rewards. The greater the participation, the more rewards a user stands to earn. The real-world application of KangaMoon has drawn a ton of interest to the project and is why market experts anticipate its launch. Given the 100x predictions, KANG is considered very cheap, as it is only priced at $0.0075 per coin. Discover the Exciting Opportunities of the Kangamoon (KANG) Presale Today! Website: https://Kangamoon.com/ Join Our Telegram Community: https://t.me/Kangamoonofficial Integrating GameFi and Play To EarnEmbark on your quest for glory. Assemble your champions, engage in epic battles or bet on your favorite fighters to earn $KANG tokens and exclusive rewards. Gain control of rare NFTs, unlock exclusive content and build alliances with fellow gamers as you ascend the ranks and leaderboards. Disclaimer: The following disclaimer is important to read and understand before engaging with Kangamoon, a play-to-earn meme coin. By accessing or participating in any activities related to Kangamoon, you acknowledge and accept the terms outlined below: 1: No Financial Advice: This whitepaper and any associated content do not constitute financial advice, investment recommendations, or solicitation to purchase Kangamoon tokens. The information provided is for informational purposes only. It is your responsibility to conduct thorough research and seek professional advice before making any financial decisions. 2: Volatility and Risks: Cryptocurrencies, including Kangamoon, are volatile and subject to significant price fluctuations. Investing in or holding Kangamoon tokens involves substantial risks, including the possibility of total loss. Past performance is not indicative of future results. 3: Regulatory Compliance: The regulatory environment surrounding cryptocurrencies is evolving and varies across jurisdictions. It is your responsibility to ensure compliance with applicable laws and regulations in your country or region before engaging with Kangamoon. 4: Uncertain Market: The market for meme coins and play-to-earn platforms is highly speculative and subject to rapid changes. There is no guarantee of market demand, liquidity, or utility for Kangamoon tokens. Token values may fluctuate drastically and may not reflect the intrinsic value of the project. Contact Details Kangamoon marketing@kangamoon.com Company Website https://kangamoon.com/

February 20, 2024 09:00 AM Central Standard Time

Image
Article thumbnail News Release

Troy Media

EDMONTON – TheNewswire - Feb 20 2024 - The Alberta Hemp Alliance is hosting an Hemp Industry Conference – THE FUTURE IS HERE, Wednesday February 21 st though Friday the 23 rd at the Renaissance Airport Hotel in Edmonton. The event features tours, networking, and presentations about the extraordinary progress being made in developing this new innovative industry contributing to Alberta’s economic diversification: research, processing and manufacturing, food and fibre materials. Tours include the Agricvalue Processing Business Incubator in Leduc, the Bio Processing Innovation Centre in the Edmonton Research Park, and Natural Fibre Technologies manufacturing plant in South Edmonton. Keynote Speakers include the Minister of Agriculture RJ Sigurdson, Darren Bodar of Hempalta, Angus Watt of NBF Wealth Management, and Malcolm Bruce of Edmonton Global. A highlight will include the announcement of two new major manufacturing projects for the Region, each featuring collaboration among municipal, business and indigenous partners. FOR MORE visit https://conference.albertahempalliance.com/ and to access media opportunities please contact: Perry Kinkaide pkinkaide@shaw.ca (780) 990-5874

February 20, 2024 09:45 AM Eastern Standard Time

Article thumbnail News Release

Filament Health announces FDA opening of IND application for substance abuse disorder

Filament Health Corp

Filament Health CEO Ben Lightburn joined Steve Darling from Proactive to share the groundbreaking news that the U.S. Food and Drug Administration (FDA) has given its approval for the Investigational New Drug application for PEX010, Filament Health's botanical psilocybin drug candidate designed for the treatment of Substance Use Disorders. This development paves the way for Filament Health to commence research activities in the United States, focusing on the potential use of their botanical psilocybin drug candidate in addressing substance use disorders, including those involving opioids. Lightburn went on to explain that the IND-opening protocol had previously been submitted to Health Canada and had received the department's no-objection status, underlining the company's commitment to adhering to rigorous regulatory standards on both sides of the border. Moreover, Lightburn highlighted the extensive scope of research and collaboration surrounding PEX010. Currently, a network of 24 research institutions and licensing partners across Canada, the USA, Europe, and Israel is actively studying PEX010 for various conditions. These include but are not limited to alcohol use disorder, depression, and coma, showcasing the versatile potential of this botanical psilocybin drug candidate in addressing a wide range of medical conditions. The acceptance of the IND application by the FDA marks a pivotal moment in Filament Health's journey, offering a pathway for innovative and potentially transformative treatments for substance use disorders. It also underscores the company's global reach and collaborative efforts in advancing the field of psychedelic medicine. This milestone is a testament to the commitment of Filament Health to research and develop solutions that hold promise for individuals struggling with these challenging conditions. Contact Details Proactive North America Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

February 20, 2024 09:40 AM Eastern Standard Time

Video
1 ... 400401402403404 ... 3753